Nanoscope Therapeutics' Optogenetic Gene Therapy to be Featured in Presentation at Stanford University's Innovate Retina Summit Dec. 11, 2021
BEDFORD, Texas, Dec. 8, 2021 /PRNewswire/ -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing optogenetic gene therapies for treatment of retinal degenerative diseases, announced today the company's Multi-Characteristic Opsin (MCO) gene therapy platform will be featured in a presentation by Michael Singer, M.D., a member of Nanoscope's Clinical Advisory Board, at Stanford University's Innovate Retina summit on December 11, 2021.
Dr. Singer is Clinical Professor of Ophthalmology at the University of Texas Health Science Center in San Antonio, Texas, and Director of Clinical Research at Medical Center Ophthalmology Associates in San Antonio. His presentation is part of a program titled "Global Innovation in Retina" organized by Stanford University School of Medicine's Byers Eye Institute. Online registration is free.
Nanoscope's MCO optogenetic gene therapy is in clinical development for vision restoration in people blinded by retinitis pigmentosa (RP) regardless of genetic mutations. Nanoscope is conducting a multicenter Phase 2b trial in the U.S. (NCT04945772). Results are expected in Q4 2022. In a Phase 1/2a trial, the RP patients experienced restoration of vision to a level sufficient to resume activities of daily living.
"I am very thrilled about the potential for this new therapy for patients with retinitis pigmentosa," Dr. Singer said. "The prospect of visual restoration in these nearly blind patients is incredibly exciting."
Dr. Singer's presentation, titled "Nanoscope Therapeutics: Introduction and Perspectives," begins at 8:42 am Pacific Standard Time followed by his participation in a panel discussion.
"We are pleased Dr. Singer is presenting our unique MCO platform aimed at helping millions of people worldwide who suffer from retinal diseases," said Sulagna Battacharya, CEO of Nanoscope. "Dr. Singer has been instrumental in advising the company as its advances its clinical development programs not only in RP, but also for Stargardt disease and age-related macular degeneration."
About Nanoscope Therapeutics Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/nanoscope-therapeutics-optogenetic-gene-therapy-to-be-featured-in-presentation-at-stanford-universitys-innovate-retina-summit-dec-11-2021-301440130.html
SOURCE Nanoscope Therapeutics